Atlas Wealth’s abrdn Life Sciences Investors HQL Stock Holding History

Atlas Wealth’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$304K	Buy	+15,170	New	+$268K	0.04%	141
2024 Q3	–	Sell	-83,322	Closed	-$1.19M	–	116
2024 Q2	$1.19M	Buy	+83,322	New	+$1.13M	0.14%	97
2023 Q4	–	Sell	-24,969	Closed	-$311K	–	108
2023 Q3	$311K	Buy	24,969 +11,879	+91%	+$156K	0.06%	136
2023 Q2	$177K	Buy	+13,090	New	+$181K	0.03%	179

Other funds holding HQL

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $13B AUM 71.84% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

NIM

Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return

1WA

180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

Atlas Wealth's HQL Position: Q2 2026 in Review

Atlas Wealth opened a new position in abrdn Life Sciences Investors (HQL) in Q2 2026: 15,170 shares worth $304K. The stake represents 0.04% of the portfolio and ranks #141 among its holdings. This is a return to the name: Atlas Wealth previously reported a position in HQL as recently as Q2 2024.

Atlas Wealth first reported a position in HQL in Q2 2023 and has held it in 4 quarters since. The position peaked at $1.19M in Q2 2024. 83 funds tracked by Wall St. Rank hold HQL as of Q2 2026.

Atlas Wealth held 15,170 shares of abrdn Life Sciences Investors worth $304K as of Q2 2026.
abrdn Life Sciences Investors was a new Atlas Wealth position in Q2 2026.
abrdn Life Sciences Investors made up 0.04% of Atlas Wealth's portfolio in Q2 2026, its #141 holding.
Atlas Wealth first reported a position in abrdn Life Sciences Investors in Q2 2023 and has held it in 4 quarters since.
Atlas Wealth's abrdn Life Sciences Investors position peaked at $1.19M in Q2 2024.
83 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2026.

Based on Atlas Wealth's 13F filing for Q2 2026, filed 28 Jul 2026.